Retinal sensitivity above macular neovascularization under anti-VEGF therapy in exudative neovascular age-related macular degeneration

Retinal sensitivity above macular neovascularization under anti-VEGF therapy in exudative neovascular age-related macular degeneration

Abstract Purpose Growth of macular neovascularization (MNV) associated with development of complete retinal pigment epithelial and outer retina atrophy (cRORA) been observed in eyes neovascular age-related macular degeneration (nAMD) under effective anti-vascular endothelial growth factor (VEGF) the...

Full description

Saved in:

Bibliographic Details
Main Authors:	Laurenz Pauleikhoff, Martin Ziegler, Isabel Bachmeier, Siqing Yu, Beatriz Garcia Armendariz, Daniel Pauleikhoff
Format:	Article
Language:	English
Published:	BMC 2025-03-01
Series:	BMC Ophthalmology
Subjects:	Exudative nAMD anti-VEGF therapy Macular atrophy (cRORA) Retinal function Microperimetry
Online Access:	https://doi.org/10.1186/s12886-025-03946-8
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

OCT-Defined Atrophic Age-Related Macular Degeneration Changes Associated with Deep Visual Sensitivity Losses: A Multicenter Study
by: Zhichao Wu, BAppSc(Optom), PhD, et al.
Published: (2025-11-01)

Efficacy and Safety of Aflibercept Biosimilars Relative to Reference Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis
by: Aljuhani HS, et al.
Published: (2025-06-01)

Faricimab versus the standard of care for neovascular age-related macular degeneration in Italy: an indirect treatment comparison
by: Carlotta Galeone, et al.
Published: (2024-12-01)

The role of peripheral blood microRNAs in the pathogenesis and treatment response of age-related macular degeneration
by: Meng Kong, et al.
Published: (2025-12-01)

Etiopathogenesis of non-exudative age-related macular degeneration (literature review)
by: M. M. Bikbov, et al.
Published: (2022-03-01)

Analysis of Clinical Study Results Obtained in Patients with Neovascular Age-Related Macular Degeneration in 2005–2020. Review
by: N. A. Gavrilova, et al.
Published: (2022-04-01)

Outcomes of Anti-VEGF Therapy in Eyes with Diabetic Macular Edema, Vein Occlusion-Related Macular Edema, and Neovascular Age-Related Macular Degeneration: A Systematic Review
by: Aldokhail LS, et al.
Published: (2024-12-01)

Adherence to Anti-VEGF Treatment in Patients with Neovascular Age-Related Macular Degeneration: A Real-World Study
by: Mekala Shellvarajah, et al.
Published: (2025-04-01)

Safety and effectiveness of brolucizumab in patients with neovascular age-related macular degeneration: A phase IV study from India
by: Asim K Ghosh, et al.
Published: (2025-06-01)

Exploiting Microperimetry as a Functional End Point in Healthy Aging and Different Stages of Age-Related Macular Degeneration
by: Johannes Schrittwieser, MD, et al.
Published: (2025-11-01)

Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to routine clinical practice
by: R. R. Fayzrakhmanov
Published: (2019-06-01)

Patient Preference on Age-Related Macular Degeneration Treatment: A Systematic Review
by: Kawasaki A, et al.
Published: (2025-05-01)

Optical Coherence Tomography Angiography Flow Signal in Non-Treatment-Naïve Patients with Neovascular Age-Related Macular Degeneration Treated with Faricimab
by: Max Brinkmann, et al.
Published: (2025-02-01)

Discordance Among Patients and Ophthalmologists Regarding the Burden of Intravitreal Injections
by: Robinson K, et al.
Published: (2025-08-01)

The first Russian register of patients with neovascular age-related macular degeneration: a real-world clinical study
by: V. V. Neroev, et al.
Published: (2023-12-01)

Analysis of intravitreal using of anti vegf-medications for diseases of fundus accompanied by exudation and neovascularization
by: N. G. Zavgorodnya, et al.
Published: (2013-08-01)

Plasma and Urine Metabolites Associated with Microperimetric Retinal Sensitivity in Age-Related Macular Degeneration
by: Krupa Sourirajan, et al.
Published: (2025-03-01)

Principles of anti-VEGF dosing in the treatment of neovascular age-related macular degeneration
by: I. E. Ioshin, et al.
Published: (2019-08-01)

Long-Term Outcomes of Nonadherence to Anti-VEGF Therapy in Advanced Neovascular Age-Related Macular Degeneration
by: A. N. Kulikov, et al.
Published: (2022-10-01)

Comparison of optical coherence tomography vs. fluorescein angiography-based macular neovascularization classifications in age-related macular degeneration
by: Gábor G. Deák, et al.
Published: (2025-02-01)

Metformin inhibits pathological retinal neovascularization but promotes retinal fibrosis in experimental neovascular age-related macular degeneration
by: Xin Wang, et al.
Published: (2025-03-01)

Real-world outcomes of a loading phase with intravitreal faricimab in refractory Neovascular Age-Related Macular Degeneration (nAMD) patients
by: Xu Yufeng, et al.
Published: (2025-07-01)

A pilot study : retinal sensitivity change in neovascular age-related macular degeneration patients with better baseline visual acuity
by: Jae Hyup Lee, et al.
Published: (2024-11-01)

Onset of End-Stage Atrophic Age-Related Macular Degeneration as an End Point—A Delphi Study: Classification of Atrophy Meetings Report 7
by: Zhichao Wu, BAppSc(Optom), PhD, et al.
Published: (2025-09-01)

Bilateral improvement in age-related macular degeneration following unilateral Aflibercept injection
by: Muhammad Irfan Karamat, et al.
Published: (2024-12-01)

Initial experience with brolucizumab for neovascular age-related macular degeneration (nAMD) in India – Multicentric, real-world study
by: Deependra Vikram Singh, et al.
Published: (2024-12-01)

Evidence for Whom? A Systematic Review of Eligibility Criteria in RCTs of Anti-VEGF for Neovascular Age-Related Macular Degeneration
by: Andreas Arnold-Vangsted, et al.
Published: (2025-07-01)

Short-term Outcomes of Anti-VEGF therapy in Neovascular Age-related Macular Degeneration with Initially Low Visual Acuity
by: A. N. Kulikov, et al.
Published: (2025-03-01)

Vitrectomy for full-thickness macular hole developed during aflibercept treatment for wet age-related macular degeneration
by: Agnieszka Nowosielska
Published: (2024-12-01)

Modeling pegcetacoplan treatment effect for atrophic age-related macular degeneration with AI-based progression prediction
by: Irmela Mantel, et al.
Published: (2025-02-01)

The Economic Burden of Anti-Vascular Endothelial Growth Factor on Patients and Caregivers in the UK, Europe, and North America
by: David Tabano, et al.
Published: (2025-06-01)

The Vascular Architecture of Macular Neovascularization in Age-Related Macular Degeneration as a Predictor of Therapy Requirements: A 3-Year Longitudinal Analysis
by: Michael Grün, et al.
Published: (2025-04-01)

Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration
by: Hang A, et al.
Published: (2024-12-01)

Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF
by: H. Mhmud, et al.
Published: (2025-06-01)

Real-World-Data of Treatment-Naïve and Previously Treated Patients Receiving Up to 3 Injections of Faricimab in Neovascular Age-Related Macular Degeneration
by: Kunzmann BC, et al.
Published: (2024-12-01)

Tailored Anti-VEGF Therapy with New Generation Optimizations (TANGO) Treatment Regimen for Neovascular Age-Related Macular Degeneration: Rationale, Design, and Simulation Study
by: Subhi Y, et al.
Published: (2025-04-01)

Variation in Mesopic Retinal Sensitivity Relative to Distance from Geographic Atrophy in Age-Related Macular Degeneration
by: Souvick Mukherjee, PhD, et al.
Published: (2025-11-01)

Clinical Evaluation of the Effectiveness of Neovascular Age-related Macular Degeneration Combined Treatment
by: L. A. Golota, et al.
Published: (2025-03-01)

Efficacy of aflibercept in patients with neovascular age-related macular degeneration when combined with cataract surgery
by: A. A. Kuznetsov, et al.
Published: (2018-10-01)

12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept
by: Wajiha J Kheir, et al.
Published: (2025-01-01)